Significant Accounting Policies - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2024 USD ($) Leases	Dec. 31, 2023 USD ($)
Schedule Of Significant Accounting Policies [Line Items]
Allowance for credit loss	$ 0	$ 0
Impairment of inventory	$ 0	$ 500,000
Number of operating leases | Leases	2
Change in Accounting Principle, Accounting Standards Update, Adopted [true false]	true
Change in Accounting Principle, Accounting Standards Update, Adoption Date	Jan. 01, 2024
Accounting Standards Update [Extensible Enumeration]	us-gaap:AccountingStandardsUpdate202307Member
Minimum [Member]
Schedule Of Significant Accounting Policies [Line Items]
Accounts receivable standard payment terms	30 days
Estimated useful lives of assets	3 years
Maximum [Member]
Schedule Of Significant Accounting Policies [Line Items]
Accounts receivable standard payment terms	60 days
Estimated useful lives of assets	5 years
Accounts Receivable [Member] | Customer Concentration Risk [Member] | ANI Pharmaceuticals, Inc. [Member]
Schedule Of Significant Accounting Policies [Line Items]
Percentage of concentration risk	72.30%	67.80%
Accounts Receivable [Member] | Customer Concentration Risk [Member] | OncoSil Medical Ltd [Member]
Schedule Of Significant Accounting Policies [Line Items]
Percentage of concentration risk	16.50%
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Ocumension Therapeutics [Member]
Schedule Of Significant Accounting Policies [Line Items]
Percentage of concentration risk		15.70%
Sales Revenue, Net [Member] | Customer Concentration Risk [Member] | ANI Pharmaceuticals, Inc. [Member]
Schedule Of Significant Accounting Policies [Line Items]
Percentage of concentration risk	93.60%	73.20%
Sales Revenue, Net [Member] | Customer Concentration Risk [Member] | Besse Medical [Member]
Schedule Of Significant Accounting Policies [Line Items]
Percentage of concentration risk		17.20%